CMO Pillar5, selected by IntelGenx to manufacture its high-strength CPI-300 bupropion hydrochloride antidepressant, has passed its FDA pre-approval inspection with no Form 483 being issued. The agency visited Pillar5's Arnprior, Ontario manufacturing facility, a former Pfizer plant that dates from 1956. Pillar5 moved in in 2009 and employs about 100. IntelGenx release